CBM / Cambrex Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

CBM / Cambrex Corp. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* Cambrex Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) 12/31/2019 (Date of Event Which R

CBM / Cambrex Corp. 15-12B - - 15-12B

15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-10638 333-59273 Cambrex Corporation (Exact name of registrant as

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

CBM / Cambrex Corp. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

Amended and Restated Certificate of Incorporation of Cambrex Corporation

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CAMBREX CORPORATION FIRST: The name of the Corporation is Cambrex Corporation (hereinafter the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Corporat

Amended and Restated Bylaws of Cambrex Corporation

EX-3.2 EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF CAMBREX CORPORATION A Delaware Corporation Effective December 4, 2019 TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 1 Section 2.3 Special Meetings 1 Section 2.4 Notice 2 Section 2.5 Adjournments 2 S

Cambrex Announces Completion of Acquisition by the Permira Funds

EX-99.1 Exhibit 99.1 Cambrex Announces Completion of Acquisition by the Permira Funds December 4, 2019 EAST RUTHERFORD, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) — Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced the completion of its previously announced sale to an affili

Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 4, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission File

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 16, 2019, pursuant to the provisions of Rule 12d2-2 (a).

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATI

Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Results

EX-99.1 Exhibit 99.1 NEWS RELEASE Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Results East Rutherford, NJ - October 24, 2019 - Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that in connection with the debt portion of the financing for the pen

Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 23, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission File

CBM / Cambrex Corp. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission File

CBM / Cambrex Corp. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission File

CBM / Cambrex Corp. DEFM14A - - DEFM14A

DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CBM / Cambrex Corp. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 23, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commi

Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement

EX-99.1 Exhibit 99.1 Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement EAST RUTHERFORD, N.J., September 23, 2019 /PRNewswire/ — Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day “go shop” period under the previously announced Agreement and Plan of Merger

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 23, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission Fi

CBM / Cambrex Corp. PREM14A - - PREM14A

PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CBM / Cambrex Corp. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2019 CAMBREX CORPORATION (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission File N

Amended and Restated Bylaws of Cambrex Corporation, effective August 6, 2019

EX-3.1 Exhibit 3.1 AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION ARTICLE I – OFFICES The registered office of Cambrex Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation shall have offices at such other places as the board of directors of the Corporation (the “Board of Directors” or the “Board”) m

Gregory P. Sargen Amended and Restated Employment Agreement, dated August 6, 2019

EX-10.4 Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED AGREEMENT made by and between CAMBREX CORPORATION, a Delaware corporation (the “Company”), and Gregory P. Sargen, (the “Employee”), as of the 6th day of August, 2019. WHEREAS, the Employee presently is a key management employee of the Company, namely its Executive Vice President, Chief Financial Officer; WHERE

Steven M. Klosk Employment Agreement, dated August 6, 2019

EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT made by and between CAMBREX CORPORATION, a Delaware corporation (the “Company”), and Steven M. Klosk, (the “Employee”), as of the 6th day of August, 2019. WHEREAS, the Employee presently is a key management employee of the Company, namely its President & Chief Executive Officer; and WHEREAS, the Board of Directors of the Company (the “Board”

Agreement and Plan of Merger, dated as of August 7, 2019 (the “Merger Agreement”), by and among the Company, Catalog Intermediate Inc., and Catalog Merger Sub Inc. (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on August 8, 2019)

EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among CATALOG INTERMEDIATE INC., CATALOG MERGER SUB INC. and CAMBREX CORPORATION Dated as of August 7, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Index of Defined Terms 12 1.3 Certain Interpretations 15 ARTICLE II THE MERGER 17 2.1 The Merger 17 2.2 The Effective Time 1

Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash

EX-99.1 Exhibit 99.1 Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash East Rutherford, NJ – August 7, 2019 – Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced today that it has signed a definitive agreement to be acquired by an affiliate of the Permir

Shawn P. Cavanagh Amended and Restated Employment Agreement, dated August 6, 2019

EX-10.3 Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED AGREEMENT made by and between CAMBREX CORPORATION, a Delaware corporation (the “Company”), and Shawn P. Cavanagh, (the “Employee”), as of the 6th day of August, 2019. WHEREAS, the Employee presently is a key management employee of the Company, namely its Executive Vice President & Chief Operating Officer; WHER

Samantha Hanley Employment Agreement, dated August 6, 2019

EX-10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT THIS AGREEMENT made by and between CAMBREX CORPORATION, a Delaware corporation (the “Company”), and Samantha M. Hanley, (the “Employee”), as of the 6th day of August, 2019. WHEREAS, the Employee presently is a key management employee of the Company, namely its Senior Vice President, General Counsel & Secretary; and WHEREAS, the Board of Directors of the Co

CBM / Cambrex Corp. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

CBM / Cambrex Corp. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

Dorothy Brienza Offer of Employment Letter

Exhibit 10.1 May 15, 2019 Dear Dottie, The Cambrex management team enjoyed meeting with you throughout the interview process and I am delighted to extend an offer of employment to you to join Cambrex as Senior Vice President and Chief Human Resources Officer. As we discussed, you will report to Shawn and me and receive an annual base salary of $375,000 per year. You will also be eligible for a bon

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (E

CAMBREX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS - Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference call at 8:30 a.m. ET on M

` Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS - Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference call at 8:30 a.m. ET on May 2, 2019 - East Rutherford, NJ – May 2, 2019 – Cambrex Corporation (NYSE: CBM), the leading small molecule company provi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2019 CAMBREX CORPORATION (Exact name of Registrant as Specified in Its Charter) DELAWARE 1-10638 22-2476135 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2019 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

CBM / Cambrex Corp. DEFA14A

DEFA14A 1 cbm-defa14a20181231.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a

CBM / Cambrex Corp. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of

CAMBREX CORPORATION AND SUBSIDIARIES UNAUDITED PRO FORMA CONDENSED COMBINED INCOME STATEMENTS For the Year Ended December 31, 2017 (in thousands, except per share data) Cambrex Halo Avista Reclassifications Pro Forma Adjustments Pro Forma Combined Gr

EX-99.3 Exhibit 99.3 Unaudited Pro Forma Condensed Combined Financial Information The following unaudited pro forma condensed combined financial statements of Cambrex Corporation (the “Company”), Halo Pharmaceutical, Inc. (“Halo”) and Avista Pharma Solutions, Inc. (“Avista”) have been prepared to give effect to the acquisitions of Halo and Avista by Cambrex Corporation. As reported in the Current

Financial Statements and Exhibits

8-K/A 1 d718523d8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2019 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of

Contents Consolidated interim financial statements (unaudited) Consolidated balance sheets 2 Consolidated statements of operations and comprehensive loss 3 Consolidated statements of redeemable convertible preferred stock and stockholders’ deficit 4

EX-99.2 Exhibit 99.2 Avista Pharma Solutions, Inc. Consolidated Financial Report September 30, 2018 Contents Consolidated interim financial statements (unaudited) Consolidated balance sheets 2 Consolidated statements of operations and comprehensive loss 3 Consolidated statements of redeemable convertible preferred stock and stockholders’ deficit 4 Consolidated statements of cash flows 5 Notes to c

Contents Report of independent certified public accountants 1 Financial statements Balance sheet 2 Statement of operations 3 Statement of redeemable convertible preferred stock and stockholders’ deficit 4 Statement of cash flows 5 Notes to financial

EX-99.1 Exhibit 99.1 Avista Pharma Solutions, Inc. Financial Report December 31, 2017 Contents Report of independent certified public accountants 1 Financial statements Balance sheet 2 Statement of operations 3 Statement of redeemable convertible preferred stock and stockholders’ deficit 4 Statement of cash flows 5 Notes to financial statements 6-18 Report of Independent Certified Public Accountan

Cambrex Corporation | One Meadowlands Plaza | East Rutherford, NJ 07073 Phone 201.804.3000 | Fax 201.804.9852 | www.cambrex.com FINANCIAL RESULTS - Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding cust

Exhibit 99.1 NEWS RELEASE Cambrex Corporation | One Meadowlands Plaza | East Rutherford, NJ 07073 Phone 201.804.3000 | Fax 201.804.9852 | www.cambrex.com CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS - Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Conference call at 8:30 a.m. ET on February 13, 2019 - East

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2019 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fil

Form of Restricted Stock Agreement under 2009 Long-Term Incentive Plan (A)

exhibit 10.14 CAMBREX CORPORATION 2009 LONG-TERM INCENTIVE PLAN rESTRICTED STOCK UNIT AGREEMENT THIS RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”) entered into as of , by and between (the “Participant”) and Cambrex Corporation, a Delaware corporation (the “Company”), evidences the grant of Restricted Stock Units (the “Award”) under the Cambrex Corporation 2009 Long-Term Incentive Plan, as amen

Agreement and Plan of Merger, dated November 19, 2018, by and among Cambrex Corporation, Avista Pharma Solutions, Inc., Aviator Merger Sub, Inc., Ampersand 2007 Limited Partnership and Ampersand 2011 Limited Partnership (A)

EXHIBIT 2.2 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER Among CAMBREX CORPORATION AVIATOR MERGER SUB, INC. AVISTA PHARMA SOLUTIONS, INC. THE SIGNATORY STOCKHOLDERS PARTY HERETO and AMPERSAND 2011 LIMITED PARTNERSHIP AS THE STOCKHOLDERS’ REPRESENTATIVE Dated as of November 19, 2018 741638551 table of contents ARTICLE I DEFINITIONS; CERTAIN RULES OF CONSTRUCTION. 1 ARTICLE II MERGER AND CONVERSIO

CBM / Cambrex Corp. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Cambrex Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) 12/31/2018 (Date of Event Which R

Form of Restricted Stock Unit Agreement under 2012 Equity Incentive Plan for Non-Employee Directors (A)

EXHIBIT 10.17 CAMBREX CORPORATION 2012 EQUITY INCENTIVE PLAN FOR NON-EMPLOYEE DIRECTORS Restricted Stock Unit – Award Agreement This award agreement (the “Agreement”) sets forth the terms of the award (the “Award”), described below, of Restricted Stock Units (the “RSUs”) under the Cambrex Corporation 2012 Equity Incentive Plan for Non-Employee Directors (the “Plan”) to the Participant identified b

Subsidiaries of the Registrant (A)

EXHIBIT 21.1 CAMBREX CORPORATION EXHIBIT 21.1 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany Cambrex High Point, Inc. Delaware Cambrex Whippany Delaware Cambrex Mirabel Canada

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number 1‑10638 CAMBREX CORPORATION (Exact n

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2019 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

Amended and Restated By-Laws of Cambrex Corporation

DRAFT Exhibit 3.1 AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION ARTICLE I – OFFICES The registered office of Cambrex Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation shall have offices at such other places as the board of directors of the Corporation (the “Board of Directors” or the “Board”) ma

CBM / Cambrex Corp. / VANGUARD GROUP INC Passive Investment

cambrexcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Cambrex Corp Title of Class of Securities: Common Stock CUSIP Number: 132011107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designat

Credit Agreement, dated January 2, 2019, by and among Cambrex Corporation, the subsidiary borrowers party thereto, the subsidiary guarantors party thereto, Wells Fargo Bank, National Association, as administrative agent, and the lenders party thereto from time to time (U)

EXHIBIT 10.1 Execution Version Published CUSIP Number: 13201FAG1 Revolving Credit CUSIP Number: 13201FAJ5 Term Loan CUSIP Number: 13201FAH9 $800,000,000 AMENDED AND RESTATED CREDIT AGREEMENT dated as of January 2, 2019 among CAMBREX CORPORATION The SUBSIDIARY BORROWERS Party Hereto The SUBSIDIARY GUARANTORS Party Hereto The LENDERS Party Hereto WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administra

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

8-K 1 cbm-8k20190102.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2019 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of inc

Combined Financial Statements and Report of Independent Certified Public Accountants Halo Pharmaceutical And AFFILIATES December 31, 2017 and 2016

Exhibit 99.1 Combined Financial Statements and Report of Independent Certified Public Accountants Halo Pharmaceutical And AFFILIATES December 31, 2017 and 2016 Halo Pharmaceutical And AFFILIATES table of contENTS Page Report of Independent Certified Public Accountants 1 Combined Financial Statements Combined Balance Sheets 2 Combined Statements of Comprehensive Income 3 Combined Statements of Chan

2 CAMBREX CORPORATION AND SUBSIDIARIES UNAUDITED PRO FORMA CONDENSED COMBINED INCOME STATEMENTS For the Year Ended December 31, 2017 (in thousands, except per share data)

Exhibit 99.3 Unaudited Pro Forma Condensed Combined Financial Information The following unaudited pro forma condensed combined financial statements of Cambrex Corporation (“Cambrex” or the “Company”) and Halo Pharmaceutical and Affiliates (“Halo”) have been prepared to give effect to the acquisition of Halo by Cambrex Corporation. On September 12, 2018, the Company completed the acquisition of Hal

Combined Interim Financial Statements (Unaudited) and Review Report of Independent Certified Public Accountants Halo Pharmaceutical And AFFILIATES June 30, 2018 and 2017

Exhibit 99.2 Combined Interim Financial Statements (Unaudited) and Review Report of Independent Certified Public Accountants Halo Pharmaceutical And AFFILIATES June 30, 2018 and 2017 Halo Pharmaceutical And AFFILIATES table of contENTS Page Combined Interim Financial Statements Combined Balance Sheets 3 Combined Statements of Comprehensive Income 4 Combined Statements of Changes in Stockholders’ E

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission

Forward-Looking Statements Statements in this presentation regarding the acquisition of Avista Pharma Solutions (“Avista”) and expected benefits therefrom (including revenue and earnings expectations and the expected accretive effect of the transacti

Cambrex to Acquire Avista Pharma Solutions November 20, 2018 Exhibit 99.1 Forward-Looking Statements Statements in this presentation regarding the acquisition of Avista Pharma Solutions (“Avista”) and expected benefits therefrom (including revenue and earnings expectations and the expected accretive effect of the transaction in 2019), future financial and operating results, outlook, growth, prospe

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 19, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d652110d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of i

CAMBREX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS - Acquired Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base – - Conference call at 8:30 a.m. ET on November 8, 2018 -

EX-99.1 Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS - Acquired Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base – - Conference call at 8:30 a.m. ET on November 8, 2018 - East Rutherford, NJ – November 8, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceu

CBM / Cambrex Corp. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATI

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commissio

CBM / Cambrex Corp. 8-K (Current Report)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fi

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fi

CAMBREX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS - Net Revenue increased 13% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 - - 2018 full year Adjusted Net Revenue Growth and Adjusted EBITDA guidance reaff

EX-99.1 2 d599891dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS - Net Revenue increased 13% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 - - 2018 full year Adjusted Net Revenue Growth and Adjusted EBITDA guidance reaffirmed - - Agreement to acquire Halo Pharma, broadening capabilities, enhancing revenue g

Purchase and Sale Agreement, dated July 20, 2018, by and among Cambrex Corporation, Halo Pharmaceutical, Inc., 8121117 Canada Inc., Halo Pharmaceutical Canada Inc., the Sellers party thereto, SK Capital Partners, L.P., as Sellers’ Representative, and SK Angel Holdings, L.P., as Seller Guarantor.

Exhibit 2.1 execution version PURCHASE AND SALE AGREEMENT by and among CAMBREX CORPORATION, THE ACQUIRED COMPANIES, THE PERSONS SIGNATORY HERETO AS SELLERS, SK ANGEL HOLDINGS, L.P. AND THE SELLERS’ REPRESENTATIVE Dated as of July 20, 2018 6983841211 Table of Contents Page Article I DEFINITIONS1 Section 1.1 Definitions1 Article II PURCHASE AND SALE1 Section 2.1 Purchase and Sale of the Interests1 S

CBM / Cambrex Corp. 10-Q (Quarterly Report)

10-Q 1 cbm-10q20180630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file numbe

CBM / Cambrex Corp. 8-K (Current Report)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fil

Forward-Looking Statements Statements in this presentation regarding the acquisition of Halo Pharma (“Halo”) and expected benefits therefrom (including revenue and earnings expectations), future financial and operating results, outlook, growth, prosp

EX-99.1 Cambrex to Acquire Halo Pharma July 23, 2018 Exhibit 99.1 Forward-Looking Statements Statements in this presentation regarding the acquisition of Halo Pharma (“Halo”) and expected benefits therefrom (including revenue and earnings expectations), future financial and operating results, outlook, growth, prospects, business strategies, future market position, future operating environment and

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File Numb

CAMBREX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS - Net Revenue increased 34% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 - - 2018 full year financial guidance reaffirmed - - Conference call at 8:30 a.m.

Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS - Net Revenue increased 34% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 - - 2018 full year financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on May 3, 2018 - East Rutherford, NJ – May 3, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small mol

CBM / Cambrex Corp. 10-Q (Quarterly Report)

10-Q 1 cbm-10q20180331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file numb

CBM / Cambrex Corp. 8-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

CBM / Cambrex Corp. DEFA14A

DEFA14A 1 cbm-defa14a20180426.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm

CBM / Cambrex Corp. DEF 14A

DEF 14A 1 cbm-def14a20180426.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary P

CBM / Cambrex Corp. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Cambrex Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) 12/31/2017 (Date of Event Which R

CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS - Net Revenue increased 2.5% for the fourth quarter and 9% for the full year 2017- - Conference call at 8:30 a.m. ET on February 8, 2018 -

EX-99.1 2 ex104600.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS - Net Revenue increased 2.5% for the fourth quarter and 9% for the full year 2017- - Conference call at 8:30 a.m. ET on February 8, 2018 - East Rutherford, NJ – February 8, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and ge

Financial Statements and Exhibits, Results of Operations and Financial Condition

cbm201802078k.htm CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2018 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction o

CBM / Cambrex Corp. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number 1-10638 CAMBREX CORPORATION (Exa

Subsidiaries of the Registrant (A)

CAMBREX CORPORATION EXHIBIT 21.1 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany Cambrex High Point, Inc. Delaware

CBM / Cambrex Corp. / VANGUARD GROUP INC Passive Investment

cambrexcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Cambrex Corp Title of Class of Securities: Common Stock CUSIP Number: 132011107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designat

CBM / Cambrex Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CAMBREX CORP (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

CBM / Cambrex Corp. ESP

November 27, 2017 Ms. Christine Torney Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Dear Ms. Torney: This letter is Cambrex Corporation?s (?the Company?) response to your letter to the Company dated November 17, 2017, regarding the Company?s Form 10-K for the Fiscal Year Ended December 31, 2016 (File No. 001-10638). For your convenience, the Staff?s comment

CBM / Cambrex Corp. FORM 8-K (Current Report)

cbm201711068k.htm CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction o

CAMBREX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS - Net Revenue increased 13% and EBITDA increased 29% vs. prior year quarter - - 2017 full year financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on November 7, 2017 -

ex99440.htm Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS - Net Revenue increased 13% and EBITDA increased 29% vs. prior year quarter - - 2017 full year financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on November 7, 2017 - East Rutherford, NJ ? November 7, 2017 ? Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2017 [ ] TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPO

Amended and Restated By Laws of Cambrex Corporation (D)

ex98790.htm Exhibit 3.1 (Marked to show changes) AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION ARTICLE I ? OFFICES The registered office of Cambrex Corporation (the ?Corporation?) in the State of Delaware shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation shall have offices at such other places as the board of directors of the Corporation (the ?Board o

Cambrex FORM 8-K (Current Report/Significant Event)

cbm20171102b8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporatio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

cbm201711028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction (Commission File

GREGORY B. BROWN M.D. APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION

ex98738.htm Exhibit 99.1 NEWS RELEASE GREGORY B. BROWN M.D. APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION East Rutherford, NJ ? November 3, 2017 ? Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Gregory B. Brown, M.D. was appointed to the Company?s Board of Directors on Octob

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201708038k.htm CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of

CAMBREX REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS - Net Revenue increased 13% and EBITDA increased 16% vs. prior year quarter - - 2017 full year financial guidance for Adjusted EBITDA and free cash flow increased - - Conference call at 8:30 a.m.

ex99-1.htm Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS - Net Revenue increased 13% and EBITDA increased 16% vs. prior year quarter - - 2017 full year financial guidance for Adjusted EBITDA and free cash flow increased - - Conference call at 8:30 a.m. ET on August 4, 2017 - East Rutherford, NJ – August 4, 2017 – Cambrex Corporation (NYSE: CBM), a leading manufact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2017 [ ] TRANSITION REPORT PURSUAN

10-Q 1 cbm2017063010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission fi

Cambrex FORM 10-Q (Quarterly Report)

cbm2017033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-1063

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201705038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Co

CAMBREX REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS - Net Revenue increased 11% and EBITDA increased 26% vs. prior year quarter - - 2017 full year financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on May 4, 2017 -

ex99-1.htm Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS - Net Revenue increased 11% and EBITDA increased 26% vs. prior year quarter - - 2017 full year financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on May 4, 2017 - East Rutherford, NJ ? May 4, 2017 ? Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201705018k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation)

Cambrex FORM DEF 14A

cbm20170313def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Co

CBM / Cambrex Corp. / VANGUARD GROUP INC Passive Investment

cambrexcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Cambrex Corp Title of Class of Securities: Common Stock CUSIP Number: 132011107 Date of Event Which Requires Filing of this Statement: February 28, 2017 Check the appropriate box to designat

Cambrex SC 13G/A (Passive Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Cambrex Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31, 2016 (Date of Event

CBM / Cambrex Corp. / VANGUARD GROUP INC Passive Investment

cambrexcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Cambrex Corp Title of Class of Securities: Common Stock CUSIP Number: 132011107 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designat

Cambrex FORM 10-K (Annual Report)

cbm2016123110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number 1-10638 CAMBR

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 cbm201702028k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction o

CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS - Gross Sales increased 14% in the fourth quarter and 13% for the full year 2016 - - 2017 Net Revenues expected to grow between 7% and 11% - - Conference call at 8:30 a.m. ET on Febr

ex99-1.htm Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS - Gross Sales increased 14% in the fourth quarter and 13% for the full year 2016 - - 2017 Net Revenues expected to grow between 7% and 11% - - Conference call at 8:30 a.m. ET on February 3, 2017 - East Rutherford, NJ ? February 3, 2017 ? Cambrex Corporation (NYSE: CBM), a leading manufacturer o

CAMBREX CORPORATION Subsidiaries of Registrant

ex21.htm CAMBREX CORPORATION EXHIBIT 21 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany Zenara Pharma Private Limited India Cambrex High Point, Inc. Delaware

Employment Agreement, dated January 20, 2017, between Cambrex Corporation and Tom Vadaketh (N)

ex10-21.htm Exhibit 10.21 EMPLOYMENT AGREEMENT THIS AGREEMENT made by and between CAMBREX CORPORATION, a Delaware corporation (the "Company"), and Tom Vadaketh, (the "Employee"), as of the 20th day of January, 2017. WHEREAS, the Employee presently is a key management employee of the Company, namely its Executive Vice President & Chief Financial Officer; and WHEREAS, the Board of Directors of the C

Tom Vadaketh Offer of Employment Letter (M)

ex10-20.htm Exhibit 10.20 December 30, 2016 Mr. Tom Vadaketh 2124 E 23 Street Tulsa, OK 74114 Dear Tom, The Cambrex management team enjoyed meeting with you throughout the interview process and I am delighted to extend an offer of employment to you to join Cambrex as Executive Vice President & Chief Financial Officer. You will report to me and receive an annual base salary of $400,000 per year. Yo

CAMBREX CORPORATION POWER OF ATTORNEY

poavadaketh.htm Exhibit 24 CAMBREX CORPORATION POWER OF ATTORNEY KNOW all by those present, that the undersigned hereby constitutes and appoints SAMANTHA HANLEY and DANIELLE MANN, and each of them, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of CAMBREX CORPORATION (the ?Company?), or its subsid

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201701038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2017 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation)

CAMBREX REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS - Sales increased 8% in the quarter, full year sales and profit guidance increased - - Acquisition of North Carolina based PharmaCore completed - - Conference call at 8:30 a.m. ET on November 4, 20

EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE CAMBREX REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS - Sales increased 8% in the quarter, full year sales and profit guidance increased - - Acquisition of North Carolina based PharmaCore completed - - Conference call at 8:30 a.m. ET on November 4, 2016 - East Rutherford, NJ – November 4, 2016 – Cambrex Corporation (NYSE: CBM), a leading m

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201611038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation

Cambrex FORM 10-Q (Quarterly Report)

cbm2016081710q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201610308k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation

BERNHARD HAMPL APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION

ex99-1.htm Exhibit 99.1 NEWS RELEASE BERNHARD HAMPL APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION East Rutherford, NJ ? October 31, 2016 ? Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Bernhard Hampl was appointed to the Company?s Board of Directors on October 27, 2016, and

CAMBREX REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Sales increased 12% for the quarter and full year sales and profit guidance increased - - New $50 million production facility in Iowa completed and in operation - - Conference call at 8:30 a.m.

ex99-1.htm Exhibit 99.1 Date: July 28, 2016 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Sales increased 12% for the quarter and full year sales and profit guidance increased - - New $50 million production facility in Iowa completed and in operation - - Conf

Financial Statements and Exhibits, Results of Operations and Financial Condition

cbm201607278k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (

Cambrex FORM 10-Q (Quarterly Report)

cbm2016063010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

cbm201605188k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (C

CREDIT AGREEMENT dated as of May 18, 2016 CAMBREX CORPORATION The SUBSIDIARY BORROWERS Party Hereto The SUBSIDIARY GUARANTORS Party Hereto The LENDERS Party Hereto WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent JPMORGAN CHASE BANK, N

EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Published CUSIP Number: 13201FAE6 Revolving Credit CUSIP Number: 13201FAF3 $500,000,000 CREDIT AGREEMENT dated as of May 18, 2016 among CAMBREX CORPORATION The SUBSIDIARY BORROWERS Party Hereto The SUBSIDIARY GUARANTORS Party Hereto The LENDERS Party Hereto WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent JPMORGAN CHASE BANK, N.A. as Sy

CAMBREX REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Sales increased 20% and EBITDA increased 52% vs. prior year quarter - - 2016 financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on April 29, 2016 -

EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Date: April 29, 2016 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Sales increased 20% and EBITDA increased 52% vs. prior year quarter - - 2016 financial guidance reaffirmed - - Conference call at 8:30 a.m. ET on

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201604288k.htm CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of

Cambrex FORM 10-Q (Quarterly Report)

cbm2016033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-1063

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201604228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation)

CAMBREX CORPORATION POWER OF ATTORNEY

glassell.htm CAMBREX CORPORATION POWER OF ATTORNEY KNOW all by these presents, that the undersigned hereby constitutes and appoints SAMANTHA HANLEY and DANIELLE MANN, and each of them, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of CAMBREX CORPORATION (the ?Company?), or its sub

Cambrex FORM DEF 14A

cbm20160314def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

cbm201603148k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation)

CLAES GLASSELL APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION

ex99-1.htm Exhibit 99.1 Innovation. Experience. Performance. NEWS RELEASE CLAES GLASSELL APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION East Rutherford, NJ ? March 16, 2016 ? Cambrex Corporation (NYSE: CBM, ?Cambrex?) announced today that on March 14, 2016, Claes Glassell was appointed to the Company?s Board of Directors for a term expiring on the date of its 2016 annual meeting and wi

CBM / Cambrex Corp. / VANGUARD GROUP INC Passive Investment

cambrexcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Cambrex Corp Title of Class of Securities: Common Stock CUSIP Number: 132011107 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate box to designat

CAMBREX CORPORATION Subsidiaries of Registrant

ex21.htm CAMBREX CORPORATION EXHIBIT 21 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany Zenara Pharma Private Limited India

CBM / Cambrex Corp. 10-K - Annual Report - FORM 10-K

cbm2015123110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10638 CAMBR

CBM / Cambrex Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CAMBREX CORP (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

Gregory P. Sargen Offer of Employment Letter (I)

ex10-19.htm Exhibit 10.19 Luke M. Beshar Senior Vice President and Chief Financial Officer Direct Line: 201.804.3010 [email protected] February 3, 2003 Mr. Gregory P. Sargen Dear Greg: I am pleased to confirm the details of our offer of employment as Vice President- Finance of Cambrex Corporation, reporting to me. This position will have the responsibility for managing all aspects of Cambrex

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 cbm201602088k.htm FORM 8-K CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other

CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS - 2015 Sales and EBITDA increased 16% and 57% respectively vs. prior year - - Continued strong sales and EBITDA growth expected in 2016 - - Conference call at 8:30 a.m. ET on Februar

ex99-1.htm Exhibit 99.1 Date: February 9, 2016 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS - 2015 Sales and EBITDA increased 16% and 57% respectively vs. prior year - - Continued strong sales and EBITDA growth expected in 2016 - - Conference cal

CBM / Cambrex Corp. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Cambrex Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31, 2015 (Date of Event W

TEXT OF

ex3-1.htm Exhibit 3.1 TEXT OF AMENDMENTS TO THE BY-LAWS OF CAMBREX CORPORATION Article III, Section 3.a of the By-Laws is amended to read as follows: Section 3. NUMBER, ELECTION AND TERMS. (a) Any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors. The term "entire Board" as u

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

8-K 1 cbm201601298k.htm FORM 8-K CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 28, 2016 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other

Cambrex ESP

cbm20151217corresp.htm December 18, 2015 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Dear Mr. Rosenberg: This letter is Cambrex Corporation?s (?the Company?) response to your letter to the Company dated December 11, 2015, regarding the Company?s Form 10-K for Fiscal Year Ended December 31, 2014, and Fo

LOUIS J. GRABOWSKY APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION

ex99-1.htm Exhibit 99.1 Innovation. Experience. Performance. NEWS RELEASE LOUIS J. GRABOWSKY APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION East Rutherford, NJ ? November 5, 2015 ? Cambrex Corporation (NYSE: CBM, ?Cambrex?) announced today that on November 2, 2015, Louis J. Grabowsky, age 64, was appointed to the Company?s Board of Directors for a term expiring on the date of its 2016

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 cbm201511058k.htm FORM 8-K CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201511028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2015 [ ] TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPO

CAMBREX REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS - Sales increased 14% (19% excluding foreign exchange) and EBITDA increased 31% vs. prior year quarter - - Profit guidance increased for 2015 - - Conference call at 8:30 a.m. ET on November 3, 2015

ex99-1.htm Exhibit 99.1 Date: November 3, 2015 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS - Sales increased 14% (19% excluding foreign exchange) and EBITDA increased 31% vs. prior year quarter - - Profit guidance increased for 2015 - - Conference call at 8:30

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 cbm201508218k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 19, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of

Cambrex Corporation 2009 Long-Term Incentive Plan (as amended and restated, effective April 29, 2015) (P)

ex4-3.htm Exhibit 4.3 CAMBREX CORPORATION 2009 LONG TERM INCENTIVE PLAN (as amended and restated, effective April 29, 2015) 1. Purpose. The purpose of the Cambrex Corporation 2009 Long-Term Incentive Plan, as amended, is to assist in aligning the interests of eligible participants with those of the Company?s stockholders by providing long-term incentive compensation opportunities tied to the perfo

Cambrex FORM S-8

cbm20150731s8.htm As filed with the Securities and Exchange Commission on August 3, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CAMBREX CORPORATION (Exact name of registrant as specified in its charter) Delaware 22-2476135 (State or other jurisdiction of incorporation or organiza

CAMBREX REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS - Sales increased 9% (15% excluding foreign exchange) and EBITDA increased 63% vs. prior year quarter - - Sales and profit guidance increased significantly for the full year 2015 - - Conference ca

ex99-1.htm Exhibit 99.1 Date: July 30, 2015 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS - Sales increased 9% (15% excluding foreign exchange) and EBITDA increased 63% vs. prior year quarter - - Sales and profit guidance increased significantly for the full ye

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2015 [ ] TRANSITION REPORT PURSUAN

cbm2015063010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638

Cambrex FORM 8-K (Current Report/Significant Event)

cbm201507298k.htm CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of i

Cambrex 8-K (Current Report/Significant Event)

CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2015 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (

CAMBREX REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Sales increased 18% (27% excluding currency) and EBITDA increased $9.6 million vs. prior year quarter - - Strong sales and EBITDA growth continue to be expected in 2015 - - Conference call at 8:3

Date: May 1, 2015 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Sales increased 18% (27% excluding currency) and EBITDA increased $9.6 million vs. prior year quarter - - Strong sales and EBITDA growth continue to be expected in 2015 - - Conference call at 8:30

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

CONFORMED COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Co

Cambrex DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of

Cambrex PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement o Confidential, For Use of

CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS - 2014 Sales of $374.2 million and EBITDA of $82.1 million significantly exceed guidance - - Strong sales and EBITDA growth expected in 2015 - - Conference call at 8:30 a.m. ET on Fe

Exhibit 99.1 Date: February 6, 2015 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS - 2014 Sales of $374.2 million and EBITDA of $82.1 million significantly exceed guidance - - Strong sales and EBITDA growth expected in 2015 - - Conference call at 8

CAMBREX CORPORATION Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany Zenara Pharma Private Li

CAMBREX CORPORATION EXHIBIT 21 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany Zenara Pharma Private Limited India

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1?10638 CAMBREX CORPORATION (Exact n

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2015 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

CAMBREX REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS - Solid third quarter results reported and strong fourth quarter expected - - Full year 2014 Adjusted income from continuing operations per share guidance increased - - Conference call at 8:30 a.m.

Exhibit 99.1 Date: October 30, 2014 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS - Solid third quarter results reported and strong fourth quarter expected - - Full year 2014 Adjusted income from continuing operations per share guidance increased - - Conference

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2014 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2014 o TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATI

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2014 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

CAMBREX REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Strong second quarter and first half results reported - - Full year 2014 sales and profit guidance increased - - Conference call at 8:30 a.m. ET on August 1, 2014 -

Exhibit 99.1 Date: August 1, 2014 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Strong second quarter and first half results reported - - Full year 2014 sales and profit guidance increased - - Conference call at 8:30 a.m. ET on August 1, 2014 - East Rutherfor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2014 o TRANSITION REPORT PURSUANT TO

10-Q 1 form10q.htm CAMBREX CORPORATION 10-Q 6-30-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to

JAMES F. WINSCHEL APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION

Exhibit 99.1 Innovation. Experience. Performance. NEWS RELEASE JAMES F. WINSCHEL APPOINTED TO THE BOARD OF DIRECTORS OF CAMBREX CORPORATION East Rutherford, NJ – May 29, 2014 – Cambrex Corporation (NYSE: CBM, “Cambrex”) announced today that James F. Winschel, Jr., age 64, was appointed to the Company’s Board of Directors for a term expiring on the date of its 2015 annual meeting and will serve on

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CAMBREX CORPORATION 8-K 5-29-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2014 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2014 o TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (

CAMBREX REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS - Company confirms full year 2014 sales and profit guidance and expects a very strong second quarter - - Conference call at 8:30 a.m. ET on May 2, 2014 -

Exhibit 99.1 Date: May 2, 2014 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS - Company confirms full year 2014 sales and profit guidance and expects a very strong second quarter - - Conference call at 8:30 a.m. ET on May 2, 2014 - East Rutherford, NJ – May 2, 20

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 form8k.htm CAMBREX CORPORATION 8-K 5-2-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2014 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other ju

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - CAMBREX CORPORATION 8-K 4-24-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2014 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

SHLOMO YANAI ELECTED NON-EXECUTIVE CHAIRMAN OF CAMBREX CORPORATION - John R. Miller Retires -

Exhibit 99.1 NEWS RELEASE SHLOMO YANAI ELECTED NON-EXECUTIVE CHAIRMAN OF CAMBREX CORPORATION - John R. Miller Retires - East Rutherford, NJ – April 24, 2014 – Cambrex Corporation (NYSE: CBM, “Cambrex”) announced today that the Board of Directors has elected Shlomo Yanai as its new Non-Executive Chairman of the Board effective immediately following the retirement of John R. Miller. Mr. Miller has s

- CAMBREX CORP DEF 14A 4-24-2014

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a—6(e)(2)) x Definitive Proxy Statement o Definitive additional materials o Soliciting material under Rule 14a-12 Cambrex Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORPORATION 8-K 2-11-2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2014 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fil

CAMBREX CORPORATION Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany

CAMBREX CORPORATION EXHIBIT 21 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 o TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1‑10638 CAMBREX CORPORATION (Exact n

CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS - Strong increase in fourth quarter and full year Sales and EBITDA – - Expect another year of strong sales and EBITDA growth in 2014 - - Conference call at 8:30 a.m. ET on February 1

Exhibit 99.1 Date: February 11, 2014 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS - Strong increase in fourth quarter and full year Sales and EBITDA – - Expect another year of strong sales and EBITDA growth in 2014 - - Conference call at 8:30 a.m

CBM / Cambrex Corp. / HEARTLAND ADVISORS INC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CAMBREX CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31st, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

JOINT FILING AGREEMENT

EX-1 2 v364717ex-1.htm JOINT FILING AGREEMENT EXHIBIT 1 – JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing with the other reporting person of a statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0.10 par value, of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2013 o TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATI

CAMBREX REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS - Strong increase in third quarter Sales and EBITDA - - Full year 2013 guidance tightened - - Company to host conference call at 8:30 a.m. ET on November 1, 2013 -

Exhibit 99.1 Date: November 1, 2013 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS - Strong increase in third quarter Sales and EBITDA - - Full year 2013 guidance tightened - - Company to host conference call at 8:30 a.m. ET on November 1, 2013 - East Rutherford,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2013 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORPORATION 8-K 8-1-2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2013 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

Exhibit 10.30*

Exhibit 10.30 CAMBREX CORPORATION 2009 LONG-TERM INCENTIVE PLAN STOCK OPTION AGREEMENT THIS AGREEMENT (this “Agreement”) made and entered into as of the day of , 20, by and between CAMBREX CORPORATION (the “Corporation”), and «Name» (the “Optionee”), evidences the grant to Optionee on (the “Grant Date”) of an option (the “Stock Option”) to purchase the number of shares of Common Stock specified be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2013 o TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (E

- CAMBREX CORPORATION S-8 8-1-2013

S-8 1 forms8.htm CAMBREX CORPORATION S-8 8-1-2013 As filed with the Securities and Exchange Commission on August 1, 2013. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CAMBREX CORPORATION (Exact name of issuer as specified in its charter) Delaware 22-2476135 (State of Incorporation) (

CAMBREX REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS - Company confirms full year sales and profit guidance, expects strong second half - - Company to host conference call at 8:30 a.m. ET on August 1, 2013 -

Date: August 1, 2013 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS - Company confirms full year sales and profit guidance, expects strong second half - - Company to host conference call at 8:30 a.m. ET on August 1, 2013 - East Rutherford, NJ – August 1, 2013 –

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 23(b) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement of our report dated February 7, 2013, relating to the consolidated financial statements, the effectiveness of Cambrex Corporation’s internal control over financial reporting, and schedule of Cambrex Corporation appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Exhibit 10.3*

Exhibit 10.3 CAMBREX CORPORATION 2012 EQUITY INCENTIVE PLAN FOR NON-EMPLOYEE DIRECTORS STOCK OPTION AGREEMENT THIS AGREEMENT (this “Agreement”) made and entered into as of the day of , 20, by and between CAMBREX CORPORATION (the “Corporation”), and «Name» (the “Optionee”), evidences the grant to Optionee on (the “Grant Date”) of an option (the “Stock Option”) to purchase the number of shares of St

CAMBREX REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS - Company reports strong first quarter sales and operating profit growth - - Company to host conference call at 8:30 a.m. ET on May 3, 2013 -

Exhibit 99.1 Date: May 3, 2013 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS - Company reports strong first quarter sales and operating profit growth - - Company to host conference call at 8:30 a.m. ET on May 3, 2013 - East Rutherford, NJ – May 3, 2013 – Cambrex

Exhibit 10.1*

Exhibit 10.1 CAMBREX CORPORATION 2009 LONG TERM INCENTIVE PLAN (as amended and restated, effective April 25, 2013) 1. Purpose. The purpose of the Cambrex Corporation 2009 Long Term Incentive Plan is to further align the interests of eligible participants with those of the Company?s shareholders by providing long-term incentive compensation opportunities tied to the performance of the Company and i

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORPORATION 8-K 5-3-2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2013 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2013 o TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders - CAMBREX CORPORATION 8-K 4-25-2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2013 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

- CAMBREX CORP DEF 14A 4-25-2013

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a—6(e)(2)) x Definitive Proxy Statement o Definitive additional materials ¨ Soliciting material under Rule 14a-12 Cambrex Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required.

- CAMBREX CORP PRE 14A 4-25-2013

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a—6(e)(2)) o Definitive Proxy Statement o Definitive additional materials ¨ Soliciting material under Rule 14a-12 Cambrex Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required.

CBM / Cambrex Corp. / Neuberger Berman Group LLC - NONE Passive Investment

SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* CAMBREX CORP (Name of Issuer) Common (Title of Class of Securities) 13201110W (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Form of Performance Share Agreement under 2009 Long-Term Incentive Plan (Q)

EXHIBIT 10.5 CAMBREX CORPORATION 2009 LONG-TERM INCENTIVE PLAN PERFORMANCE SHARE AGREEMENT THIS PERFORMANCE SHARE AGREEMENT (the “Agreement”) entered into as of , by and between (the “Participant”) and Cambrex Corporation, a Delaware corporation (the “Company”), evidences the grant of performance-based Restricted Stock Units (the “Award”) under the Cambrex Corporation 2009 Long-Term Incentive Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 o TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (Exact n

CAMBREX CORPORATION Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany

CAMBREX CORPORATION EXHIBIT 21 Subsidiaries of Registrant Subsidiary Incorporated in: Cambrex Charles City, Inc. Iowa Cambrex Profarmaco Milano S.r.l. Italy Cambrex Karlskoga AB Sweden AS Cambrex Tallinn Estonia Cambrex IEP GmbH Germany 85

CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS - Company reports strong fourth quarter and full year sales and profit growth; continued growth expected in 2013 - - Company to host conference call at 8:30 a.m. ET on February 7, 20

Exhibit 99.1 Date: February 6, 2013 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS - Company reports strong fourth quarter and full year sales and profit growth; continued growth expected in 2013 - - Company to host conference call at 8:30 a.m. ET

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORP 8-K 2-6-2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2013 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

CAMBREX CORPORATION ANNOUNCES APPOINTMENT OF SHLOMO YANAI AS VICE CHAIRMAN OF THE BOARD OF DIRECTORS - Former President and CEO of Teva to work with Cambrex team on growth initiatives -

EXHIBIT 99.1 Innovation. Experience. Performance. NEWS RELEASE CAMBREX CORPORATION ANNOUNCES APPOINTMENT OF SHLOMO YANAI AS VICE CHAIRMAN OF THE BOARD OF DIRECTORS - Former President and CEO of Teva to work with Cambrex team on growth initiatives - East Rutherford, NJ – November 29, 2012 – Cambrex Corporation (NYSE: CBM) announced that Shlomo Yanai was appointed to its Board of Directors yesterday

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CAMBREX CORP 8-K 11-29-2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2012 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2012 o TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATI

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORPORATION 8-K 11-5-2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2012 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

CAMBREX REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS - Company reports strong third quarter sales growth; expects to meet 2012 guidance, including EBITDA growth of 15% to 23% - - Company to host conference call at 4:45 p.m. ET on November 5, 2012 -

EXHIBIT 99.1 Date: November 5, 2012 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS - Company reports strong third quarter sales growth; expects to meet 2012 guidance, including EBITDA growth of 15% to 23% - - Company to host conference call at 4:45 p.m. ET on Nov

-

September 7, 2012 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporate Finance Washington, DC Dear Mr. Rosenberg: This letter is Cambrex Corporation’s (“the Company”) response to your letter to the Company dated August 27, 2012, (the “Comment Letter”) regarding the Company’s 2011 Form 10-K, (File No. 001-10638). The Company acknowledges th

CAMBREX ANNOUNCES SIGNIFICANT NEW SUPPLY AGREEMENT

Exhibit 99.1 NEWS RELEASE CAMBREX ANNOUNCES SIGNIFICANT NEW SUPPLY AGREEMENT East Rutherford, NJ – August 14, 2012 – Cambrex Corporation (NYSE: CBM, “Cambrex”) announced that it has entered into an agreement to supply an active pharmaceutical ingredient for a customer’s Phase 3 program during 2013 and 2014. Under this non-exclusive supply arrangement, Cambrex will manufacture and deliver Phase 3 a

Regulation FD Disclosure, Financial Statements and Exhibits - CAMBREX CORPORATION 8-K 8-14-2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2012 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File

Exhibit 10.31*

Exhibit 10.31 CAMBREX CORPORATION 2009 LONG-TERM INCENTIVE PLAN PERFORMANCE SHARE AGREEMENT THIS PERFORMANCE SHARE AGREEMENT (the “Agreement”) entered into as of , by and between (the “Participant”) and Cambrex Corporation, a Delaware corporation (the “Company”), evidences the grant of performance-based Restricted Stock Units (the “Award”) under the Cambrex Corporation 2009 Long-Term Incentive Pla

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (E

Exhibit 32**

Exhibit 32 CAMBREX CORPORATION Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Quarterly Report of Cambrex Corporation (the “Company”) on form 10-Q for the period ending June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORPORATION 8-K 8-1-2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2012 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

CAMBREX REPORTS SECOND QUARTER 2012 RESULTS

Exhibit 99.1 Date: August 1, 2012 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS SECOND QUARTER 2012 RESULTS East Rutherford, NJ – August 1, 2012 – Cambrex Corporation (NYSE: CBM) reports second quarter results for the period ended June 30, 2012. Highlights - Reported sales increased by 14.3%, and e

Cambrex Corporation 2012 Equity Incentive Plan for Non-Employee Directors (S)

Exhibit 10.34 CAMBREX CORPORATION 2012 EQUITY INCENTIVE PLAN FOR NON-EMPLOYEE DIRECTORS 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based incentive

Cambrex Corporation Executive Cash Incentive Plan (N)

Exhibit 10.33 CAMBREX CORPORATION EXECUTIVE CASH INCENTIVE PLAN This Executive Cash Incentive Plan (the “Plan”) has been established to advance the interests of Cambrex Corporation (the “Company”) by providing for the grant of Awards to eligible employees of the Company and its subsidiaries, including Awards intended to qualify for the performance-based compensation exemption (“Exempt Awards”) und

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2012 o TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-10638 CAMBREX CORPORATION (

CAMBREX REPORTS FIRST QUARTER 2012 RESULTS

Exhibit 99.1 Date: May 3, 2012 Contact: Gregory P. Sargen Executive Vice President & CFO Phone: 201-804-3055 Email: [email protected] Release: Immediate CAMBREX REPORTS FIRST QUARTER 2012 RESULTS East Rutherford, NJ – May 3, 2012 – Cambrex Corporation (NYSE: CBM) reports first quarter results for the period ended March 31, 2012. Highlights - Reported sales increased by 14.4%, and excludin

Financial Statements and Exhibits, Results of Operations and Financial Condition - CAMBREX CORPORATION 8-K 5-3-2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2012 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File Numb

AMENDED & RESTATED BY-LAWS CAMBREX CORPORATION ARTICLE I – OFFICES

EX-3.1 2 ex31.htm EXHIBIT 3.1 Exhibit 3.1 Amended and Restated By-Laws of Cambrex Corporation AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION ARTICLE I – OFFICES The registered office of Cambrex Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation shall have offices at such other places as the board

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 23(b) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement of our report dated February 7, 2012, relating to the consolidated financial statements, the effectiveness of Cambrex Corporation’s internal control over financial reporting, and schedules of Cambrex Corporation appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

- CAMBREX CORPORATION S-8 4-30-2012

As filed with the Securities and Exchange Commission on April 30, 2012. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CAMBREX CORPORATION (Exact name of issuer as specified in its charter) Delaware 22-2476135 (State of Incorporation) (I.R.S. Employer Identification No.) One Meadowland

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - CAMBREX CORPORATION 8-K 4-26-2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2012 CAMBREX CORPORATION (Exact name of Registrant as specified in its charter) DELAWARE 1-10638 22-2476135 (State or other jurisdiction of incorporation) (Commission File N

.AMENDED & RESTATED BY-LAWS CAMBREX CORPORATION By - Laws ArticleARTICLE I – OFFICES Section 1.

Exhibit 3.2 Amended and Restated By-Laws of Cambrex Corporation (marked to show changes) .AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION By - Laws ArticleARTICLE I – OFFICES Section 1. The registered office of Cambrex Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation shall have offices at such ot

Amended and Restated Certificate of Incorporation of Cambrex Corporation (C)

Exhibit 3.3 Amended and Restated Certificate of Incorporation of Cambrex Corporation AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CAMBREX CORPORATION Cambrex Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that this Amended and Restated Certificate of Incorporation has been duly adopted in accordance with Secti

- CAMBREX CORP DEF14A 4-26-2012

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a—6(e)(2)) ý Definitive Proxy Statement o Definitive additional materials ¨ Soliciting material under Rule 14a-12 Cambrex Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required.

- CAMBREX CORPORATION PRE 14A 4-26-2012

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a—6(e)(2)) o Definitive Proxy Statement o Definitive additional materials ¨ Soliciting material under Rule 14a-12 Cambrex Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required.

to Schedule 13G Joint Filing Agreement

Joint Filing Agreement Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 13, 2012 in connection with their beneficial ownership of Cambrex Corp.

CBM / Cambrex Corp. / AMERIPRISE FINANCIAL INC - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment

Schedule 13G Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Cambrex Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

to Schedule 13G

Identification and Classification of the Subsidiary Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

CBM / Cambrex Corp. / Neuberger Berman Group LLC - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* CAMBREX CORP (Name of Issuer) Common (Title of Class of Securities) 13201110W (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

CBM / Cambrex Corp. / SNYDER CAPITAL MANAGEMENT L P Passive Investment

CUSIP No. 132011107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) Cambrex Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 132011107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan